ClinicalTrials.gg
TerminatedNCT02376972VARIANTUpdated Oct 10, 2016

Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis

A Phase 2 interventional study of RIFAXIMIN VAGINAL TABLET 25 MG and RIFAXIMIN VAGINAL TABLET 100 MG in BACTERIAL VAGINOSIS, sponsored by Alfasigma S.p.A.. Terminated at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2016-10-10.

Sponsored by Alfasigma S.p.A. · Phase 2, Interventional, and Treatment

Why this study was terminated
According to the Recommendation of the Indipendent Data Monitoring Committee

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 82 studies in Vaginosis, Bacterial with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Vaginosis, Bacterial · United States.

Enrollment
12th of 69
392 · median 81
Started
2015
with 6 others
Phase 2
14 of 82
none open now
Registered
42nd of 82
by date

Among the 82 studies in Vaginosis, Bacterial with a site in United States, this one is the 12th largest by enrollment of the 69 interventional ones that give a count, is one of 7 that started in 2015, is one of 14 in phase 2, and was the 42nd registered.

Vaginosis, Bacterial

240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.

Browse Vaginosis, Bacterial studies →

Open to participants now

8 of the 82 studies in Vaginosis, Bacterial with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Vaginosis, Bacterial with a site in United States, or all of them as a file.
02

Study summary

THE STUDY HAS BEEN DESIGNED TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS

Read the detailed description

THIS IS A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY PLANNING TO ENROL 626 SUBJECTS AFFECTED BY BACTERIAL VAGINOSIS.

PRIMARY ENDPOINT:

TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS

SECONDARY ENDPOINT:

TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS METROGEL VAGINAL IN SUBJECTS WITH BACTERIAL VAGINOSIS.

03

Conditions studied

  • BACTERIAL VAGINOSIS

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of bacterial vaginosis with Amsel's criteria (4 out of 4 fulfilled criteria):

    • Off white (milky or gray), thin, homogeneous, adherent vaginal discharge
    • pH >4.5
    • Positive "whiff test"
    • Presence of clue cells ≥20%
  • Bacteriological diagnosis of bacterial vaginosis with Gram stain Nugent score ≥ 4 (patients may be enrolled/randomized without this result)
  • Post-menarchal, pre-menopausal female patient
  • Non-pregnant (negative urine pregnancy test at Entry Visit/V1) nor breast-feeding patient
  • Patient aged between 18 50 years, inclusively
  • Patient who is willing to be asked questions about personal medical health and sexual history
  • Patient capable of and willing to conform to the study protocol
  • Patient who have been thoroughly informed of the aim of the study and the study procedures and who provided signed and dated written form
  • Patient who agrees to abstain from intercourse during the 5 day treatment period
  • Patient who agrees also to abstain from intercourse 3 days before the scheduled visits of follow-up
  • Patient who agrees to abstain from the use of any other intravaginal product (i.e., douching, feminine deodorants sprays, tampons, spermicides, gels, foams, vaginal ring and diaphragms) during the entire study period
  • Patient who agrees to use an adequate method of birth control for the duration of the study to avoid pregnancy. Acceptable methods include a history of bilateral tubal ligation, male partner with a vasectomy, a hormonal contraceptive [oral, patch, injectable or implantable (excluding intrauterine implantable devices [IUD], intrauterine system [IUS] and vaginal rings), or abstinence
  • Patient who agrees to abstain from alcohol ingestion during the 5-day treatment period and for 1 day afterward

Exclusion criteria

Exclusion Criteria:

  • Virginity
  • Patient with other infectious causes of vulvovaginitis (e.g., candidiasis, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, active Herpes simplex lesions, or Human Papilloma Virus lesions); patients may be enrolled/randomized without these results)
  • Other vulvovaginal or cervical conditions, abnormalities or disorders confounding the interpretation of clinical response (including total hysterectomy)
  • Symptoms suggestive of pelvic inflammatory disease
  • Patient with intra uterine device (IUD), intrauterine system (IUS), or vaginal ring as method
  • Patient with severe hepatic insufficiency (Child C)
  • Patient with severe cardiac insufficiency ( - New York Heart Association classes 3 - 4)
  • Patient who will be being evaluated, including colposcopy and cervical , or being treated during the study period, for abnormal Pap test or cervical carcinoma. To note that if the Pap test will be performed at baseline, the result will be known after the randomization visit: patients may be enrolled without this result
  • Any condition or circumstance that would prevent completion of the study or interfere with analysis of study results, including a history of drug or alcohol abuse, mental illness or non-compliance with treatments or visits, immunological (including infection), hematological or neoplastic disease (including all cervical neoplastic diseases)
  • Cervical cryotherapy, loop electrosurgical excision (LEEP), cervical laser, or any other ablative or excisional cervical procedures within the last 3 months
  • Vaginal laser within the last 3 months
  • Patient with pathological laboratory values
  • Known to rifaximin
  • Known hypersensitivity to present in rifaximin, placebo or metronidazole formulations
  • Known hypersensitivity to metronidazole, either orally or topically administered, or any forms of parabens
  • Concurrent anticoagulant therapy with coumadin or warfarin
  • Menstruating or anticipated menstruation/withdrawal bleed at Entry Visit/V1 and during the drug administration
  • Patient who received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days of randomization
  • Patient who have participated in another clinical trial or have taken an drug within the last 4 weeks prior screening
  • Patient who has taken disulfuram within the last 14 days
  • Withdrawal of
  • Patient previously randomized in this study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
392 participants (actual)

Study arms

  • Experimental
    RIFAXIMIN VAGINAL TABLET 25 MG

    RIFAXIMIN VAGINAL TABLET 25 MG ADMINISTERED ONCE A DAY FOR 5 DAYS

    Drug: RIFAXIMIN VAGINAL TABLET 25 MG

  • Experimental
    RIFAXIMIN VAGINAL TABLET 100 MG

    RIFAXIMIN VAGINAL TABLET 100 MG ADMINISTERED ONCE A DAY FOR 5 DAYS

    Drug: RIFAXIMIN VAGINAL TABLET 100 MG

  • Placebo comparator
    PLACEBO VAGINAL TABLET

    PLACEBO VAGINAL TABLET ADMINISTERED ONCE A DAY FOR 5 DAYS

    Drug: PLACEBO VAGINAL TABLET

  • Active comparator
    METROGEL VAGINAL

    METROGEL VAGINAL ADMINISTERED ONCE A DAY FOR 5 DAYS

    Drug: METROGEL VAGINAL

Interventions

06

What researchers measure

Primary outcomes

  1. CLINICAL CURE OF BACTERIAL VAGINOSIS

    RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA, I.E. NORMAL PHYSIOLOGICAL DISCHARGE, NEGATIVE "WHIFF TEST", CLUE CELLS \>20%

    Time frame: Day 22-30

Secondary outcomes

  1. BACTERIOLOGICAL CURE OF BACTERIAL VAGINOSIS

    GRAM STAIN NUGENT SCORE \<4

    Time frame: Day 22-30

  2. THERAPEUTIC CURE OF BACTERIAL VAGINOSIS

    AMSEL'S CRITERIA AND GRAM STAIN NUGENT (RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA AND NUGENT SCORE \<4)

    Time frame: Day 22-30

  3. MAINTENANCE OF CLINICAL CURE OF BACTERIAL VAGINOSIS

    AMSEL'S CRITERIA (RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA)

    Time frame: Day 61-70

  4. MAINTENANCE OF BACTERIOLOGICAL CURE OF BACTERIAL VAGINOSIS

    NUGENT SCORE \<4

    Time frame: Day 61-70

  5. MAINTENANCE OF THERAPEUTIC CURE OF BACTERIAL VAGINOSIS

    AMSEL'S CRITERIA AND NUGENT SCORE (MAINTENANCE OF RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA AND NUGENT SCORE \<4)

    Time frame: 60-69 DAYS AFTER THE FIRST DAY OF TREATMENT

  6. NUMBER, INTENSITY AND TYPE OF ADVERSE EVENTS

    The incidence of adverse events to be summarized by body system and MedDRA preferred term.

    Time frame: Up to Day 70

  7. LOCAL OBJECTIVE TOLERABILITY

    Vaginal mucosa status in terms of erythema (score 0 to 3), edema (score 0 to 3), pethechial hemorrhages (absence/presence), ulcers (absence/presence)

    Time frame: Day 22-30

  8. LOCAL SUBJECTIVE TOLERABILITY

    Grade (from 0 to 4) of vaginal itching, pain and burning

    Time frame: Day 1 to Day 5

07

Study locations

1 site
  • College of Medicine Drexel University
    Philadelphia, Pennsylvania 191012-1192, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2015
First posted
Mar 3, 2015
Start
Apr 2015
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Last update
Oct 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02376972
Lead sponsor
Alfasigma S.p.A.
Collaborators
Parexel
Responsible party
Sponsor
First posted
Mar 3, 2015
Start date
Apr 2015
Primary completion
Feb 2016
Completion
Feb 2016
Last update
Oct 10, 2016

Study contacts

Raffaella Tacchi, MD
study director · Alfasigma S.p.A.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion